UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031733
Receipt number R000036232
Scientific Title Efficacy and safety of phosphate binders in patients on hemodialysis
Date of disclosure of the study information 2018/03/14
Last modified on 2018/06/05 21:38:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of phosphate binders in patients on hemodialysis

Acronym

Phosphate binders in patients on HD

Scientific Title

Efficacy and safety of phosphate binders in patients on hemodialysis

Scientific Title:Acronym

Phosphate binders in patients on HD

Region

Japan


Condition

Condition

Patients undergoing maintenance hemodialysis

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effects and safety of phosphate binders

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in serum phosphate levels, hepcidin, and FGF23 levels

Key secondary outcomes

Changes in serum iron, TSAT, ferritin levels, hemoglobin concentration, dose of erythropoiesis stimulating agents, and erythropoietin responsiveness index, and safety.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Sucroferric oxyhydroxide or ferric citrate hydrate

Interventions/Control_2

Lanthanum carbonate

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) hemodialysis duration >2 years at enrollment, and (2) hyperphosphatemia that was treated with lanthanum carbonate at least 12 weeks before enrollment.

Key exclusion criteria

(1) a history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (2) the presence of infectious disease, malignant tumors, or treatment with steroids or immunosuppressants; (3) current hospitalization

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masanori Abe

Organization

Nihon University School of Medicine

Division name

Nephrology, Hypertension and Endocrinology

Zip code


Address

30-1, Oyaguchi Kami-cho, Itabsahi-ku, Tokyo, Japan

TEL

03-3972-8111

Email

abe.masanori@nihon-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoyasu Otsuki

Organization

Nihon University School of Medicine

Division name

Nephrology, Hypertension and Endocrinology

Zip code


Address

30-1, Oyaguchi Kami-cho, Itabsahi-ku, Tokyo, Japan

TEL

03-3972-8311

Homepage URL


Email

totsuki16@gmail.com


Sponsor or person

Institute

Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

橋本みなみ内科本院(神奈川県)、優人クリニック(東京都)


Other administrative information

Date of disclosure of the study information

2018 Year 03 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 12 Month 21 Day

Date of IRB


Anticipated trial start date

2017 Year 01 Month 22 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 03 Month 14 Day

Last modified on

2018 Year 06 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036232


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name